Who's missing out? The truth behind food allergy treatment approvals
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs)...
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs)...
High-risk NMIBC: Disease overview and treatment approach Johnson & Johnson quickly identified and...
HealthVerity recently introduced HealthVerity Notes, our newest product designed to unlock the...
AI-driven mortality models are supposed to provide accurate, data-backed insights into patient...
A new peer-reviewed study from the Centers for Disease Control and Prevention (CDC) highlights the...
GLP-1 Trends: Ozempic and Semaglutide drive a 587% spike in prescriptions Prescriptions for GLP-1...
Thank you to everyone who joined us at ISPOR 2025 in Montreal. Whether you stopped by our booth,...
This is part three of a three-part series on the essential qualities of claims data for life...
This is part two of a three-part series (read part 1, part 3) on the essential qualities of claims...
This is part one of a three-part series (read part 2, part 3) on the essential qualities of claims...
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs) pose a significant health risk due to their potential to cause life-threatening reactions, such as anaphylaxis. These conditions represent a critical area...